Spermidine Human Trial Results Fail to Impress

The compound was not found to be effective against subjective cognitive decline.


Missed targetMissed target

The results of a human clinical trial for spermidine against cognitive decline have recently been published, but the results are not positive.

What is spermidine?

Spermidine is a polyamine, meaning it has two or more primary amino groups. It is naturally occurring and is widely encountered in ribosomes and living tissues. It plays a critical role in cell function and survival.

The spermidine clinical trial

Researchers set out to test if supplementation with spermidine has a beneficial effect on memory and potential effects against age-related cognitive decline.

In this randomized trial, 100 adults aged 60 to 90 years were given either spermidine or a microcrystalline cellulose placebo. The test and placebo groups were of equal size. The main criteria for trial participation was subjective cognitive decline (SCD).

SCD describes a feeling of persistent cognitive decline in cognitively healthy older persons. In a nutshell, it is the self-reported perception of worsening of memory or, more frequently, confusion. It is a form of cognitive impairment and thought to be an early sign of Alzheimer’s disease and similar dementias.

The primary endpoint was a change in memory performance when compared to pre-trial baseline levels. The researchers also looked at additional neuropsychological, behavioral, and physiological parameters as a secondary way to determine positive changes.

Unfortunately, the researchers concluded that supplementation with spermidine did not modify memory performance or biomarkers compared with the placebo group. They noted that “Exploratory analyses indicated possible beneficial effects on verbal memory and inflammation that need to be validated in future studies at higher dosage”.

What could have gone wrong?

The researchers do propose potential reasons that these results failed to impress.

The daily dose of 0.9 milligrams may have been too low to elicit significant effects on memory or the secondary biomarkers examined.

The test subjects had SCD, but at that point, cognitive function is essentially normal. It is possible that spermidine does not act as a memory booster but instead protects against memory decline. If this turns out to be the case, then that would explain the lack of results in SCD participants.

The other consideration is that biomarkers for Alzheimer’s disease, such as amyloid, tau, and phosphorylated tau, were not examined or required for trial participation. The researchers suggest that many of the participants did not have amyloid or tau pathology. That could mean that their cognitive decline may be due to other reasons and may not be amenable to dietary interventions.


Importance: Developing interventions against age-related memory decline and for older adults experiencing neurodegenerative disease is one of the greatest challenges of our generation. Spermidine supplementation has shown beneficial effects on brain and cognitive health in animal models, and there has been preliminary evidence of memory improvement in individuals with subjective cognitive decline.

Objective: To determine the effect of longer-term spermidine supplementation on memory performance and biomarkers in this at-risk group.

Outcome: In this randomized clinical trial, longer-term spermidine supplementation in participants with subjective cognitive decline did not modify memory and biomarkers compared with placebo. Exploratory analyses indicated possible beneficial effects on verbal memory and inflammation that need to be validated in future studies at higher dosage.


While the results of this particular study and its design were not positive, further studies are still needed to address the issues that it raised.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Developing a Treatment for Arthritis from Stem Cell Signals

Resarchers publishing in Aging have found that extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells (MSCs) reduce...

Creating a Noise Clock to Measure Biological Age

Publishing in Aging, the Conboy research lab has outlined the problems with existing machine learning-based clocks and created a new...

EARD2023: Using NFTs to Support Video Gaming for Good

In this talk, Lifespan.io President Keith Comito describes use cases for "Proof of Philanthropy" (PoP) dynamic NFTs - a new...

Senolytics as a Potential Back Pain Treatment

In a recent paper, researchers from McGill University in Canada have investigated how a combination of two senolytics, RG-7112 and...

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. brf57
    June 8, 2022

    .9mg. of spermidine is a very low dose. It may useful as a preventative strategy over a longer time period.
    10mg. maybe….

    • adrian1
      June 9, 2022

      SpermidineLife and Primeadine recommend 2 mg and 3 mg, respectively, for their supplements.

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.